MAIA: רווח נקי למניה (EPS TTM) MAIA Biotechnology Inc

MAIA Biotechnology develops targeted cancer immunotherapy and is currently in a high-expenditure phase with no current revenue. Patient safety is ensured through strict adherence to temperature controls during drug delivery. The rolling net income per share snapshot demonstrates financial stability, where the value of -0.48 characterizes this level. Business development relies on scientific and clinical alliances with medical centers without acquisitions.

MAIA Biotechnology (MAIA) developments in immuno-oncology remain independent of economic cycles and macro shocks. Analyzing the annual net income per share trend allows for an assessment of the business's intrinsic value. This metric compares the final financial result with the volume of securities issued. This enables the identification of the balance between asset supply and institutional capital demand. The price action of this line serves as a filter to exclude loss-making strategies.